Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2013-12-19Clinical Trial Update: High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2 [Phase 2]
A Phase 2 study assessing high-dose intravenous interleukin-2 in patients with metastatic renal cell carcinoma that did not respond to prior…
-
CLINICAL_TRIALS trial_result · 2013-12-19Clinical Trial Update: Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer [Phase 2]
Clinical trial update on a phase 2 study of vaccine therapy with or without fludarabine in stage IV renal cell carcinoma.
-
CLINICAL_TRIALS research · 2013-12-19Clinical Trial Update: Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer [Phase 2]
This clinical trial update describes a Phase 2 study of interleukin-2 in patients with metastatic or recurrent renal cell carcinoma.
-
CLINICAL_TRIALS trial_result · 2013-12-04Clinical Trial Update: Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer [Phase 2]
A Phase 2 trial evaluates a combination of interleukin-2, vinblastine, and GM-CSF for metastatic renal cell carcinoma; the current trial sta…
-
CLINICAL_TRIALS trial_result · 2013-12-03Clinical Trial Update: Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer [Phase 3]
An extension study of pazopanib (VEG105192) in patients with advanced or metastatic renal cell carcinoma has completed Phase 3 and posted re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-11-27FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2013-11-20Clinical Trial Update: AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer [Phase 2]
Phase 2 trial of cediranib (AZD2171) in patients with refractory metastatic kidney cancer was terminated, with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-11-14Clinical Trial Update: Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
The study reports disease outcomes for sorafenib in patients with advanced renal cell carcinoma treated in community oncology settings.
-
CLINICAL_TRIALS research · 2013-11-08Clinical Trial Update: A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell Carcinoma
This clinical trial update notes that the study evaluating the urinary biomarker Kidney Injury Molecule-1 for detecting renal cell carcinoma…
-
CLINICAL_TRIALS trial_result · 2013-11-06Clinical Trial Update: Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery [Phase 2]
Phase 2 clinical trial update evaluating interleukin-2 for patients with stage III or stage IV renal cell carcinoma after surgical removal o…
-
CLINICAL_TRIALS trial_result · 2013-10-11Clinical Trial Update: Research Study for Patients With Metastatic Renal Cell Carcinoma [Phase 2]
A Phase 2 clinical trial for metastatic renal cell carcinoma sponsored by Bayer has been terminated.
-
CLINICAL_TRIALS trial_result · 2013-09-24Clinical Trial Update: Comparison of Immune Response Following Surgical Management of Renal Tumors
The Emory University–sponsored trial evaluating immune response after surgical management of renal tumors has been terminated.
-
CLINICAL_TRIALS research · 2013-09-20Clinical Trial Update: Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer [Phase 2]
Phase 2 clinical trial evaluating interleukin-2 with or without histamine dihydrochloride for metastatic renal cell carcinoma (kidney cancer…
-
CLINICAL_TRIALS trial_result · 2013-09-19Clinical Trial Update: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors [Phase 1]
Phase 1 study evaluating the drug-drug interaction between cabozantinib (XL184) and rosiglitazone in subjects with solid tumors; the trial h…
-
FDA approval · 2013-09-16FDA Approved: INLYTA — Supplemental Application (U.S. Pharmaceuticals)
The FDA approved a supplemental application for INLYTA (axitinib) submitted by U.S. Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: PS-341 in Treating Patients With Metastatic Kidney Cancer [Phase 2]
A Phase 2 study evaluating PS-341 (bortezomib) in patients with metastatic kidney cancer has completed.
-
CLINICAL_TRIALS trial_result · 2013-09-05Clinical Trial Update: Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma [Phase 2]
A Phase 2 trial evaluating G250 peptide plus interleukin-2 after surgical resection of locally advanced or metastatic renal cell carcinoma w…
-
CLINICAL_TRIALS trial_result · 2013-08-30Clinical Trial Update: Vorinostat in Treating Patients With Kidney Cancer [Phase 2]
This document reports the results of a Phase 2 clinical trial of Vorinostat in patients with recurrent or stage IV renal cell carcinoma. Res…
-
FDA approval · 2013-08-30FDA Approved: SUTENT — Supplemental Application (U.S. Pharmaceuticals)
The FDA overview notes a supplemental application for Sutent (sunitinib malate) submitted by U.S. Pharmaceuticals. The submission status is …
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer [Phase 2]
Phase 2 trial evaluating oblimersen in combination with interferon alfa for metastatic renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-08-16Clinical Trial Update: Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer [Phase 2]
A Phase 2 trial evaluating sequential all-trans retinoic acid (ATRA) followed by interleukin-2 (IL-2) to modulate dendritic cells for treati…
-
CLINICAL_TRIALS withdrawal · 2013-08-13Clinical Trial Update: Study of Cryotherapy for Renal Tumors [NA]
A clinical trial studying cryotherapy for renal tumors has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer [Phase 2]
The document reports the completion of a Phase 2 clinical trial evaluating sunitinib malate given before and after surgery in patients with …
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer [Phase 3]
A Phase 3 trial evaluating sorafenib for patients at risk of relapse after nephrectomy for renal cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-08-12Clinical Trial Update: MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer [Phase 2]
Phase 2 trial update examining MRI-detected blood vessel changes in patients with stage III or IV renal cell carcinoma treated with bevacizu…